Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

Summary

The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).

Timeline

Start

2025-09-19

Primary completion

2027-07-02

Completion

2027-07-09

Drugs

Indications